Earlier Postural and Cognitive Milestones in Parkinson's Disease with Comorbid Myasthenia Gravis

BACKGROUND: The coexistence of Parkinson's disease (PD) and myasthenia gravis (MG) is poorly characterized. Overlapping axial symptoms and fatigability may complicate diagnosis and interpretation of PD-related milestones. OBJECTIVES: The aim of the study was to characterize the phenotype of coexistent PD and MG (PD + MG) and explore differences in the timing of PD-related milestones compared to matched PD-only controls. METHODS: In this matched-cohort study, PD patients with serologically and/or electrophysiologically confirmed MG were retrospectively identified from clinical records and compared with sex-, race-, age-at-PD-onset-, disease-duration-matched PD (PD-only) controls prospectively assessed within the Cincinnati Cohort Biomarker Program. Disease milestones were Hoehn & Yahr (H&Y) ≥ 3 and Montreal Cognitive Assessment (MoCA) < 26. Time-to-event analyses used Kaplan-Meier and Cox proportional-hazards models adjusted for sex, race, age-at-PD onset, and disease duration. RESULTS: We identified 21 PD + MG patients with predominantly ocular MG and autoimmune diseases. Compared to 210 matched PD-only controls, postural instability (71% vs. 12%) and cognitive impairment (57% vs. 4.8%) were more prevalent (P < 0.001). Median time from PD onset to H&Y ≥ 3 and MoCA < 26 was shorter in PD + MG, with milestones documented at or near PD diagnosis, versus 5 and 7 years in controls (P < 0.001). PD + MG patients showed increased adjusted hazard ratios (HR) for H&Y ≥ 3 (HR: 10.6; 95% confidence interval [CI], 3.83-29.4; P < 0.001) and MoCA < 26 (HR: 35.3; 95% CI, 12.8-97.1; P < 0.001). CONCLUSIONS: PD + MG was associated with earlier documented postural and cognitive milestones than matched PD-only controls, although interpretation warrants caution given the retrospective ascertainment for PD + MG cases. Oculobulbar symptoms, disproportionate axial impairment, or fluctuating weakness should prompt investigation as potential indicators of concomitant MG.

Authors

Institutions

Publication Details

Journal
Movement Disorders Clinical Practice
Published
2026-09-29
DOI
https://doi.org/10.1002/mdc3.70838
Primary Topic
Parkinson's Disease and Spinal Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Earlier Postural and Cognitive Milestones in Parkinson's Disease with Comorbid Myasthenia Gravis

Heba A. Deraz, Pasquale Maria Pecoraro, Jesus Thomas Abanto, Alberto J. Espay et al.
Movement Disorders Clinical Practice
Parkinson's Disease and Spinal Disorders
article

Earlier Postural and Cognitive Milestones in Parkinson's Disease with Comorbid Myasthenia Gravis

Heba A. Deraz, Pasquale Maria Pecoraro, Jesus Thomas Abanto, Alberto J. Espay, Blanca Talavera, Luca Marsili, Kevin R. Duque, Zheming Yu, Marilena Mangiardi, Ansley Bell
article en

Abstract

BACKGROUND: The coexistence of Parkinson's disease (PD) and myasthenia gravis (MG) is poorly characterized. Overlapping axial symptoms and fatigability may complicate diagnosis and interpretation of PD-related milestones. OBJECTIVES: The aim of the study was to characterize the phenotype of coexistent PD and MG (PD + MG) and explore differences in the timing of PD-related milestones compared to matched PD-only controls. METHODS: In this matched-cohort study, PD patients with serologically and/or electrophysiologically confirmed MG were retrospectively identified from clinical records and compared with sex-, race-, age-at-PD-onset-, disease-duration-matched PD (PD-only) controls prospectively assessed within the Cincinnati Cohort Biomarker Program. Disease milestones were Hoehn & Yahr (H&Y) ≥ 3 and Montreal Cognitive Assessment (MoCA) < 26. Time-to-event analyses used Kaplan-Meier and Cox proportional-hazards models adjusted for sex, race, age-at-PD onset, and disease duration. RESULTS: We identified 21 PD + MG patients with predominantly ocular MG and autoimmune diseases. Compared to 210 matched PD-only controls, postural instability (71% vs. 12%) and cognitive impairment (57% vs. 4.8%) were more prevalent (P < 0.001). Median time from PD onset to H&Y ≥ 3 and MoCA < 26 was shorter in PD + MG, with milestones documented at or near PD diagnosis, versus 5 and 7 years in controls (P < 0.001). PD + MG patients showed increased adjusted hazard ratios (HR) for H&Y ≥ 3 (HR: 10.6; 95% confidence interval [CI], 3.83-29.4; P < 0.001) and MoCA < 26 (HR: 35.3; 95% CI, 12.8-97.1; P < 0.001). CONCLUSIONS: PD + MG was associated with earlier documented postural and cognitive milestones than matched PD-only controls, although interpretation warrants caution given the retrospective ascertainment for PD + MG cases. Oculobulbar symptoms, disproportionate axial impairment, or fluctuating weakness should prompt investigation as potential indicators of concomitant MG.

Movement Disorders Clinical Practice
Università Campus Bio-Medico (IT), Campus Bio Medico University Hospital (IT), Carlo Forlanini Hospital (IT), Cairo University hospitals (EG), University of Cincinnati (US)
Openalex Percentile: Top 12%
Parkinson's Disease and Spinal Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.